Merck to develop biosimilars with Parexel

WHITEHOUSE STATION, N.J. — Drug maker Merck and drug industry services organization Parexel International will work together to develop biosimilars, the two said Wednesday.

Under the agreement, Parexel will give Merck BioVentures access to clinical and regulatory services for the development of biosimilars. Financial terms of the agreement were not disclosed.

“Parexel has extensive, industry-leading experience with biosimilar development, and we truly understand the scientific complexities and regulatory pathways involved,” Parexel chairman and CEO Josef von Rickenbach said. “We are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this rapidly developing market segment for the benefit of patients worldwide.”